BioCentury
ARTICLE | Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

January 8, 2021 11:46 PM UTC

Carlyle leads Abbisko’s $123M series D
Shanghai-based oncology company Abbisko Therapeutics Co. Ltd. raised $123 million in a series D round led by the Carlyle Group. The company named Warburg Pincus, OrbiMed, Lake Bleu Capital and an undisclosed Boston-based firm as joint leading investors. New investors Janchor Partners, Sage Partners, SHC, Greater Bay Area Homeland Development Fund and another undisclosed backer also participated, as did existing investors Lilly Asia Ventures, Temasek Holdings, Qiming Venture Partners, Hankang Capital and CICC Capital. Abbisko has four clinical products.

Immunology company DiCE banks $80M round
RA Capital led DiCE Molecules SV LLC’s $80 million series C round, with which the company intends to commence clinical trials of an oral IL-17 antagonist the company believes will be first-in-class. DiCE seeks to discover small molecules that target protein-protein interfaces. Also investing were Eventide Asset Management, New Leaf Venture Partners, Soleus Capital, Driehaus Capital Management, Osage University Partners and Asymmetry Capital Management, as well as existing investors Northpond Ventures, Sands Capital, Sanofi Ventures, Alexandria Venture Investments, Altitude Life Science Ventures and Agent Capital...